NCT03751436View on ClinicalTrials.gov

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 2, 2019

Primary Completion Date

July 18, 2022

Study Completion Date

August 11, 2023

Conditions
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaMetastatic Prostate Carcinoma in the Soft TissueProstate Carcinoma Metastatic in the BonePSA ProgressionStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
Interventions
DRUG

Enzalutamide

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER